Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (55882)	1/1/2020 4:30:10 PM
From: RWS	Respond to of 79474

This is Nov. 12th news, last day you referenced. I loaded up on Nov. 19th. All the scientific developments were announced in December. Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights •November 12, 2019 SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended September 30, 2019. "We finished the third quarter with a little over twelve million dollars on the balance sheet and have since added to that balance with warrants exercised since the quarter's end" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "The quarter was marked by continued clinical execution and additional clinical validation of our systemically delivered oncolytic virus, as we continued to advance two key clinical studies that will determine the design of the phase three program for pelareorep in metastatic breast cancer. Oncolytics Biotech(R) Announces Exercise of Warrants •November 12, 2019 SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing. The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

To: Doug R who wrote (55882)	1/1/2020 5:13:26 PM
From: FJV	Read Replies (1) \| Respond to of 79474

Earlier this week the FDA approved the Merck/Astrazeneca's PARP inhibitor LYNPARZA and it is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer. Biomarker-selected patients is what ONCY's predictive biomarker is doing to identify patients who will postively respond to combination therapy in multiple cancers including breast and metastatic pancreatic cancer. This week, the market connected the dots. It looks like ONCY may become a monster in 2020.